What does this research mean for the field?

The management of pediatric inflammatory bowel disease relies heavily on extrapolating adult evidence for advanced therapies, highlighting a critical need to integrate real-world evidence to establish pediatric-specific efficacy and safety. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This review aims to compare the benefit-risk balance of advanced therapies for inflammatory bowel disease in pediatric versus adult patients.

June 5, 2026Inflammatory Bowel Diseases

Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults

View Full Paper

Ask AI

Bookmark

Authors

AMAlexandre MancheronInserm CMChristine Martinez‐VinsonAssistance Publique – Hôpitaux de Paris LBLaurent BeaugerieBoston University

Discussion

Member takes

Overview

Narrative review examines the efficacy and safety of advanced therapies in children, highlighting evidence gaps compared to adults.

Key Points

This review aims to compare the benefit-risk balance of advanced therapies for inflammatory bowel disease in pediatric versus adult patients.
Conducted a narrative review of literature on advanced therapies in pediatric and adult IBD.
Analyzed the evidence regarding efficacy and safety derived from randomized controlled trials and real-world data.
Evaluated the discrepancies and challenges in pediatric therapies compared to adults.
Only infliximab, adalimumab, and ustekinumab are currently approved for treating pediatric IBD.
Serious infections are documented risks for anti-TNF therapies, but data on other therapies are limited.
Suggests that integrating real-world evidence with predictive modeling can enhance pediatric care.

Cite This Study

Mancheron et al. (2026) studied this question.

synapsesocial.com/papers/6a41c023a205e63af4cd4378 https://doi.org/10.1093/ibd/izag123

View Full Paper

Ask AI

Bookmark

June 5, 2026Inflammatory Bowel Diseases

Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults

View Full Paper

Ask AI

Bookmark

Authors

AMAlexandre MancheronInserm CMChristine Martinez‐VinsonAssistance Publique – Hôpitaux de Paris LBLaurent BeaugerieBoston University

Discussion

Member takes

Overview

Narrative review examines the efficacy and safety of advanced therapies in children, highlighting evidence gaps compared to adults.

Key Points

This review aims to compare the benefit-risk balance of advanced therapies for inflammatory bowel disease in pediatric versus adult patients.
Conducted a narrative review of literature on advanced therapies in pediatric and adult IBD.
Analyzed the evidence regarding efficacy and safety derived from randomized controlled trials and real-world data.
Evaluated the discrepancies and challenges in pediatric therapies compared to adults.
Only infliximab, adalimumab, and ustekinumab are currently approved for treating pediatric IBD.
Serious infections are documented risks for anti-TNF therapies, but data on other therapies are limited.
Suggests that integrating real-world evidence with predictive modeling can enhance pediatric care.

Cite This Study

Mancheron et al. (2026) studied this question.

synapsesocial.com/papers/6a41c023a205e63af4cd4378 https://doi.org/10.1093/ibd/izag123

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark